Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.73 |
| ▸ | HTT | P42858 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.57 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.57 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.57 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.57 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.57 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.57 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.57 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.57 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15514302 | 0.88 | HPGD (0.59) | HPGDHTTKDM4ERAB9ANPC1 | |
| Imidazole SCHEMBL4983396 | 0.86 | HPGD (0.57) | HPGDHTTKDM4ERAB9ANPC1 | |
| SCHEMBL17817603 | 0.85 | HPGD (1.00) | HPGDHTTKDM4ERAB9ANPC1 | |
| SCHEMBL16589495 | 0.84 | HPGD (0.67) | HPGDHTTKDM4ERAB9ANPC1 | |
| SCHEMBL30824255 | 0.84 | HPGD (0.67) | HPGDHTTKDM4ERAB9ANPC1 | |
| SCHEMBL30824225 | 0.82 | HPGD (0.52) | HPGDHTTKDM4ERAB9ANPC1 | |
| SCHEMBL5322245 | 0.80 | HPGD (0.61) | HPGDHTTKDM4ERAB9ANPC1 | |
| SCHEMBL4820228 | 0.79 | KDM4E (0.56) | HPGDHTTKDM4ELMNAGRIN2D | |
| SCHEMBL9703672 | 0.77 | LMNA (0.59) | HPGDHTTKDM4ELMNAGRIN2D | |
| SCHEMBL9704358 | 0.77 | GRIN2D (0.68) | HPGDHTTLMNAGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108997230-B | Quinoxaline derivative with matrix metalloproteinase inhibitory activity, preparation method and application thereof | 山东大学 | 2020-08-04 | — | — | CN | claimed |
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. | 2018-05-31 | — | — | US | claimed |
| US-20160009717-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | claimed |
| US-9145408-B2 | Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-09-29 | — | — | US | claimed |
| EP-2324013-B3 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2014-10-22 | — | — | EP | claimed |
| US-20130274265-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2013-10-17 | — | — | US | claimed |
| EP-2537844-A1 | Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof | Purdue Pharma L.P. (US) | 2012-12-26 | — | — | EP | claimed |
| EP-2324013-B1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2012-09-19 | — | — | EP | claimed |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2011-07-21 | — | — | US | claimed |
| EP-2324013-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2011-05-25 | — | — | EP | claimed |
| WO-2010010458-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2010-01-28 | — | — | WO | claimed |
| US-5633255-A | RESPIRATORY SYSTEM DISORDERS; ACID HYDROLYSIS; ALKYLATION | PIERRE FABRE MEDICAMENT (FR) | 1997-05-27 | — | — | US | claimed |
| EP-0663903-B1 | 1,2-DIHYDRO-2-OXO-3-AMINO QUINOXALINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION IN THERAPY | PF MEDICAMENT (FR) | 1997-04-23 | — | — | EP | claimed |
| US-4181724-A | Quinoxalinone compounds useful for expanding the lumina or air passages in mammals | THE UPJOHN COMPANY (US) | 1980-01-01 | — | — | US | claimed |
| US-20260027161-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | MICROBA IP PTY LTD (AU) | 2026-01-29 | — | — | US | disclosed |
| CN-110770227-B | Novel azaquinoline derivatives | 拜耳动物保健有限责任公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | PURDUE PHARMA L.P. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-0029658-A1 | Salts of dihalo-2-quinoxaline carboxylic acids, their preparation and pharmaceutical formulations containing them | ELI LILLY AND COMPANY (US) | 1981-06-03 | — | — | EP | disclosed |
| US-4264600-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-04-28 | — | — | US | disclosed |
| US-4252954-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | QDPR, P2RX4, P2RX5 | HPGD 63/4885HTT 297/4885KDM4E 1206/4885 |
| US-20130274265-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | OPRK1, OPRD1, P2RX4 | HPGD 36/4885HTT 1815/4885KDM4E 1588/4885 |
| US-20160009717-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | OPRK1, OPRD1, P2RX4 | HPGD 36/4885HTT 1815/4885KDM4E 1588/4885 |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | OPRK1, OPRD1, P2RX4 | HPGD 36/4885HTT 1815/4885KDM4E 1588/4885 |
| US-20260027161-A1 | BACTERIAL STRAINS FOR TREATING DISEASE | VIP, SI, ALPI | HPGD 4182/4885HTT 3917/4885KDM4E 4679/4885 |
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | P2RX4, OPRK1, QDPR | HPGD 31/4885HTT 463/4885KDM4E 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.